Brief: Atreca Announces FDA Clearance Of Investigational New Drug Application For ATRC-101
03/12/2019 13:23
Dec 3 (Reuters) - Atreca Inc BCEL.O :
* ATRECA ANNOUNCES FDA CLEARANCE OF INVESTIGATIONAL NEW DRUG
APPLICATION FOR ATRC-101
* ATRECA INC - EXPECTS TO INITIATE A FIRST-IN-HUMAN PHASE 1B
CLINICAL TRIAL OF ATRC-101 IN PATIENTS WITH SOLID TUMORS IN
EARLY 2020
Source text for Eikon: ID:nGNX8bcpbS
Further company coverage: BCEL.O
(((Reuters.Briefs@thomsonreuters.com);))
Recent news on Atreca
See all newsBrief: Baker Bros Advisors Reports 19.99% Passive Stake In Atreca As Of Dec 31, 2023 - SEC Filing
Brief: Immunome To Acquire Antibody-Related Assets And Materials From Atreca
Brief: Atreca Says On Dec 19 Asset Sale And Other Transactions Contemplated By Agreement, Board Approved Liquidation And Dissolution Of Co
Brief: Atreca Q3 basic EPS USD -0.92
Brief: Atreca Announces Agreement To Terminate Lease And Departure Of CFO Herb Cross